Novonesis A/s Class B · OMXCOP:NSIS_B
Novonesis A/s Class B — Shareholder Meeting (2025)
68 slides from Novonesis A/s Class B's shareholder meeting presentation, 2025
Slide 1: Novonesis Annual General Meeting 2025
Slide 2: Cees de Jong, Chair of the Board
Cees de Jong Chair of the Board hovonesis
Slide 3: Board of Directors
Board of Directors Hero Brandgaard Dalsgaard Vice Chair An lentze Holskov dsen Employee Employee Employee representative representative representative @bro Employee representative hovonesis
Slide 4: Executive Leadership Team
Executive Leadership Team “ < Ester Baiget Rainer Lehmann CEO CFO FByrick EVP, Human Health Biosolutions € MorteniE. Rasmussen EVP, People & Stakeholder Relations Henrik@erck Nielsen Chief Operating Officer EVP, Strategy & Integration Tina Sejersgard Fane EVP, Planetary Health Biosolutions Chist Sci
Slide 5: Our auditors
Our auditors ae hovonesis
Slide 6: Slide 6
Slide 7: Anders Orjan Jensen, Chair of the meeting
novonesis Anders Orjan Jensen Chair of the meeting
Slide 8: Invitation to the Annual General Meeting
hovonesis Invitation to the Annual General Meeting Seen ff Novozymes A/S the era of biosolutions hRovonesis
Slide 9: Agenda
Agenda The Board of Directors’ report on the Company's activities in the past financial year Presentation and approval of the audited Annual Report for 2024 Resolution on distribution of profit in accordance with the approved Annual Report Presentation and advisory vote on the Remuneration Report fo
Slide 10: Slide 10
Slide 11: Slide 11
Slide 12: Novonesis
iS ovones: (ey
Slide 13: Solid 2024 results
Solid 2024 results =" | > Adjusted 2 EBITDA margin Organic sales growth
Slide 14: A promising future
A promising future | » DY; Expanding our Planting the seeds for core business future accelerated growth Long-term Positive global profitable growth impact
Slide 15: Novonesis
- x » novonesis
Slide 16: Sales contributed to six UN SDGs
om apeeeteiny : i) < a ‘ ‘BS. | of sales contributed to six UN SDGs ‘Ths. #6 a Sa AP rae ee ee
Slide 17: Reducing emissions while increasing revenue
from Scopes 1 and 2 while increasing revenue hovonesis
Slide 18: Creating shareholder value
Creating shareholder va ue ~26 EUR billion Market capitalization end of 2024 11% Increase in share price vs 2023 12% Total shareholder return in 2024 hovonesis
Slide 19: Creating shareholder value
Creating shareholder value Total dividend for the year at DKK 6.20 / EUR 0.83 per share DKK 2.00 /cur 0.27 DKK 4.20/ cr 0.56 Interim dividend paid in September 2024 Proposed dividend hovonesis
Slide 20: Broad shareholder base
Broad shareholder base ~100,000 shareholders ~(0% of B shares held internationally hovonesis
Slide 21: Remuneration of the Board of Directors
iO Remuneration of the Board of Directors * Based ona fixed fee structure / N j \ f \ + Remuneration increased in 2024 due to: | \ ¢ Increased Board size after the combination / \ —_ * Establishment of an interim Integration Committee; | Fa * Introduction of supplementary fees 7 } . * More informati
Slide 22: Remuneration of the Executive Management
OOO Remuneration of the Executive Management Jr a 2024 neha S \ / \ * Short-term incentive: |. Long-term incentive program aligned * Strong performance on financial targets / with strategic priorities and sustainability targets- * Employee Engagement { \ a gs + Individual.targets —| } : o\ * Long-te
Slide 23: Board composition
a4 Board composition: * Innovati mitt 2 We lanning’ —_ > > novonesis
Slide 24: Slide 24
Slide 25: Slide 25
Slide 26: Slide 26
Slide 27: Novonesis 2024
Novonesis 2024 hovonesis
Slide 28: Strong EBITDA margin
. 4 Strong EBITDAtmargi "y 361... a ws | 1667.5 Adjusted EBITDA margin hovonesis
Slide 29: Strong sales performance across our business
Strong sales performance across our business Total revenue EUR M 3,946 8% Organic sales growth Pro forma numbers Food & Health Biosolutions EUR M 1,771 Gap, \ ee Organic sales a 5% coxu a Human Health % of sales Planetary Health Biosolutions EUR M 2,175 O% ¥ CH a Organic sales 86% growth ‘Ag, Energy
Slide 30: Working as one company
Ng as one Company % ynergy run rate M 80-90 200 Expected sales synergy run rate contribution by 2027
Slide 31: Solution
Solution
Slide 32: Becoming a unified company
Becoming a unified \ Employe gement scor - above industry benchmar}
Slide 33: Patents and years of dedication to science
patents | ¥ 6) O+ "ia years of dedicat toscience
Slide 34: Novonesis
hRovonesis
Slide 35: Real world impact
Real world impact hovonesis
Slide 36: Saving our world with biology
Sas our world with biology
Slide 37: The era of biosolutions is here to stay
Slide 38: Advocating for a regulatory path for biosolutions
Advocating for a regulatory path for biosolutions United ECONGIA IC Nations Forum n_”, Novo pas i) BIOSOLUTIONS = jordisk @ ; THE B TEAM fonden VY hovonesis
Slide 39: Organic sales growth and adjusted EBITDA margin outlook
—~+5-8.. Organic sales growth ° 3 (788.. Adjusted E argin hovonesis
Slide 40: The future is bright
3 vA oe | The future +.) isbright =|
Slide 41: People. Planet. Positive.
Slide 42: Thank you
Slide 43: Agenda
Agenda sf The Board of Directors’ report on the Company's activities in the past financial year Presentation and approval of the audited Annual Report for 2024 Resolution on distribution of profit in accordance with the approved Annual Report Presentation and advisory vote on the Remuneration Report
Slide 44: Agenda
Agenda sf The Board of Directors’ report on the Company's activities in the past financial year Presentation and approval of the audited Annual Report for 2024 Resolution on distribution of profit in accordance with the approved Annual Report Presentation and advisory vote on the Remuneration Report
Slide 45: Agenda
Agenda sf The Board of Directors’ report on the Company's activities in the past financial year Presentation and approval of the audited Annual Report for 2024 Resolution on distribution of profit in accordance with the approved Annual Report Presentation and advisory vote on the Remuneration Report
Slide 46: Agenda
Agenda sf The Board of Directors’ report on the Company's activities in the past financial year Presentation and approval of the audited Annual Report for 2024 Resolution on distribution of profit in accordance with the approved Annual Report Presentation and advisory vote on the Remuneration Report
Slide 47: Agenda
Agenda sf The Board of Directors’ report on the Company's activities in the past financial year Presentation and approval of the audited Annual Report for 2024 Resolution on distribution of profit in accordance with the approved Annual Report Presentation and advisory vote on the Remuneration Report
Slide 48: 5. Resolution on remuneration of the Board of Directors
5. Resolution on remuneration of the Board of Directors Base fee to Board of Directors « 3.5% increase in the base fee from the level in 2024 ¢ Base fee of DKK 564,800 Supplementary fees + The chairs of board committees will each receive a supplementary fee of 1.0 times the base fee ¢ The members of
Slide 49: Agenda
Agenda sf The Board of Directors’ report on the Company's activities in the past financial year Presentation and approval of the audited Annual Report for 2024 Resolution on distribution of profit in accordance with the approved Annual Report Presentation and advisory vote on the Remuneration Report
Slide 50: Slide 50
Slide 51: Jesper Brandgaard
Jesper Brandgaard
Slide 52: Novonesis
© novonesis
Slide 53: Proposed Board of Directors
Proposed Board of Directors "2 jes Heine de Jong Dalsgaard Chair of the Board Vice Chair Morten Otto A. Sommer Frederikke Robert Naddeskov Rose Jensen Spenner hovonesis
Slide 54: Slide 54
Slide 55: Cees de Jong
Cees de Jong Standing for election as Chair of the Board hovonesis
Slide 56: Heine Dalsgaard
Heine Dalsgaard Standing for election as Vice Chair hovonesis
Slide 57: Election of board members
Election of board members Morten Otto i Monila A. Sommer Kothari hovonesis
Slide 58: Employee-elected board members after the Annual General Meeting 2025
Employee-elected board members after the Annual General Meeting 2025 Robert Neddeskov Jensen Frederikke Rose Spenner hovonesis
Slide 59: Agenda
Agenda The Board of Directors’ report on the Company's activities in the past financial year Presentation and approval of the audited Annual Report for 2024 Resolution on distribution of profit in accordance with the approved Annual Report Presentation and advisory vote on the Remuneration Report fo
Slide 60: 9. Election of auditor
9. Election of auditor a hovonesis
Slide 61: Agenda
Agenda sf The Board of Directors’ report on the Company's activities in the past financial year Presentation and approval of the audited Annual Report for 2024 Resolution on distribution of profit in accordance with the approved Annual Report Presentation and advisory vote on the Remuneration Report
Slide 62: 10a. Renewal of authorization to implement capital increases
10a. Renewal of authorization to the Board of Directors to implement capital increases To renew the Board's authorization to increase the company's share capital - both with and without pre- emptive rights for existing shareholders - and to issue warrants. All three authorizations are proposed to be
Slide 63: 10b. Renewal of authorization to acquire treasury shares
10b. Renewal of authorization to the Board of Directors for the company to acquire treasury shares The authorization is proposed to be extended to April 30, 2026, and will allow the company to repurchase own shares corresponding to 10% of the share capital. The authorization will be subject to a hol
Slide 64: 10c. Authorization for distribution of extraordinary dividend
10c. Authorization to the Board of Directors for distribution of extraordinary dividend The Board to be authorized to distribute extraordinary dividends, as described in more detail the convening notice.
Slide 65: Agenda
Agenda sf The Board of Directors’ report on the Company's activities in the past financial year Presentation and approval of the audited Annual Report for 2024 Resolution on distribution of profit in accordance with the approved Annual Report Presentation and advisory vote on the Remuneration Report
Slide 66: Agenda
Agenda sf The Board of Directors’ report on the Company's activities in the past financial year Presentation and approval of the audited Annual Report for 2024 Resolution on distribution of profit in accordance with the approved Annual Report Presentation and advisory vote on the Remuneration Report
Slide 67: Slide 67
Slide 68: Thank you and see you again in 2026
Thank you and see you again in 2026